Founder and President, Applied Biomedical Science Institute, Adjunct Professor at Scripps Research. Previously, founder of Taurus Biosciences (sold to Ligand Pharmaceuticals) and Fabrus (sold to Eloxx). Deep academic/industry career in antibody genetics, biology, and protein engineering.
Vice President Discovery, Applied Biomedical Science Institute. Previously, founder/CEO at Cyclogenix, CSO at Isogenica, Haptogen. Inventor of cyclotide and CIS-Display technology.
Drug developer and Managing Director Woodside Way Ventures. Previously CMO of FivePrime Therapeutics, Sr Director Global Oncology Research at Medimmune, Director Global Oncology R&D at Amgen. Extensive experience developing advanced oncology products.
Research Fellow at Applied Biomedical Science Institute and co-inventor of IL-15 molecules and platform technologies.
The first detailed structural and genetic analysis of cow ultralong CDR3 antibodies. Featured on the cover of Cell.
Discovery, production, and characterization of cow antibody CDR3 "knob" regions independently of the antibody. This work, recently published in PNAS, establishes the knob peptide as the smallest antibody fragment.
A minireview paper on the unique features of antibodies from non-human species, including a discussion of the "nanobodies" from camelids and ultralong CDR3 regions from cow antibodies.
11011 Via Frontera, Bldg D, San Diego, CA 92127
(858) 346-6300
Mon - Fri, 8:00-5:00